title: [Chylomicron and VLDL metabolism in daunomycin-induced nephrotic rats].
abstract: Lipid metabolism in chylomicron and VLDL were examined in daunomycin-induced nephrotic rats. 1) There was no difference in intestinal cholesterogenesis between the control rats and daunomycin-induced nephrotic rats. 2) The apoprotein content of chylomicron and VLDL increased in daunomycin-induced nephrotic rats. 3) Daunomycin-induced nephrotic rats showed increases in the content of apo B-48 and C-III, and a decrease in that of apo E in chylomicron. The apoprotein composition of VLDL in daunomycin-induced nephrotic rats showed increased apo B and decreased apo E. These results suggest that increased chylomicron-cholesterol is not due to increased intestinal cholesterogenesis, but to decreased chylomicron catabolism in daunomycin-induced nephrotic rats. Increased apoprotein in VLDL may contribute to the decreased catabolism by reducing LPL activity in the plasma and increased secretion from the liver of daunomycin induced nephrotic rats.
authors.affiliation: Renal Unit, Hyogo College of Medicine, Nishinomiya, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Gomikawa
authors.forename: K
authors.initials: K
authors.lastname: Hiraoka
authors.forename: T
authors.initials: T
authors.lastname: Yamanashi
authors.forename: H
authors.initials: H
authors.lastname: Mori
authors.forename: Y
authors.initials: Y
authors.lastname: Fujita
authors.forename: Y
authors.initials: Y
authors.lastname: Takamitsu
mesh_terms: D000818:Animals; D001059:Apoproteins / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D002847:Chromatography, Agarose; D002914:Chylomicrons / Q000378:metabolism*; D003630:Daunorubicin / Q000009:adverse effects; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D008297:Male; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001059:Apoproteins; D002914:Chylomicrons; D008079:Lipoproteins, VLDL; D002784:Cholesterol; D003630:Daunorubicin